• AMX0035 reduces risk for death by nearly half in patients with ALS

    10 days ago - By Healio

    AMX0035, an investigational neuroprotective therapy, reduced the risk for death by nearly half in patients with amyotrophic lateral sclerosis according to results of an overall survival analysis from the CENTAUR trial.
    The survival benefit of AMX0035 occurred regardless of baseline use of riluzole or edaravone, either as single agents or in combination.
    “We have many reasons to be encouraged today,” Sabrina Paganoni, MD, PhD, principal investigator of the CENTAUR trial, investigator at the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and assistant
    Read more ...